A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state

PURPOSE: To evaluate the safety, pharmacokinetics and determine the recommended dose of the selective apoptotic antineoplastic drug, OSI-461 administered on a twice-daily regimen to patients with advanced solid malignancies. METHODS: In this phase I trial, 33 patients were treated with OSI-461 doses...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: O’Bryant, C. L., Lieu, C. H., Leong, S., Boinpally, R., Basche, M., Gore, L., Leonardi, K., Schultz, M. K., Hariharan, S., Chow, L., Diab, S., Gibbs, A., Eckhardt, S. G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2814254/
https://ncbi.nlm.nih.gov/pubmed/18509645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0761-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados